IGM Biosciences, Inc.
IGM Biosciences, Inc. (IGMS) Revenue
Annual & quarterly revenue history · segment & region breakdown
IGMS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsIGM Biosciences, Inc. trailing twelve-month (TTM) revenue is $0.15B, an increase of 25.77% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | +$0.00B | +25.77% |
| 2023-12-31 | $0.00B | +$0.00B | +99.25% |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income IGM Biosciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
IGM Biosciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from IGM Biosciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IGMS revenue · 4 questionsIGMS's trailing twelve-month (TTM) revenue is $0.15B. That is an increase of 25.77% year-over-year from $0.00B in FY2024.
▸ Source: FMP · IGM Biosciences, Inc. SEC filings · GAAP · IGM Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026